Thermo Fisher Scientific Inc (NYSE:TMO) Director C Martin Harris sold 360 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $180.97, for a total value of $65,149.20. Following the sale, the director now directly owns 5,312 shares in the company, valued at $961,312.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Thermo Fisher Scientific Inc (NYSE:TMO) traded up 2.29% during midday trading on Thursday, reaching $187.14. The company’s stock had a trading volume of 2,035,478 shares. The firm has a 50-day moving average price of $176.80 and a 200 day moving average price of $167.41. The stock has a market capitalization of $73.01 billion, a price-to-earnings ratio of 32.60 and a beta of 1.06. Thermo Fisher Scientific Inc has a 52-week low of $139.07 and a 52-week high of $187.54.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The business had revenue of $5 billion for the quarter, compared to analysts’ expectations of $4.92 billion. During the same period in the prior year, the firm earned $2.03 earnings per share. Thermo Fisher Scientific’s revenue was up 10.2% compared to the same quarter last year. Equities research analysts predict that Thermo Fisher Scientific Inc will post $9.35 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Stockholders of record on Friday, September 15th will be paid a dividend of $0.15 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $0.60 annualized dividend and a dividend yield of 0.32%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.45%.

WARNING: This article was originally published by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/c-martin-harris-sells-360-shares-of-thermo-fisher-scientific-inc-tmo-stock/1534850.html.

Several hedge funds have recently added to or reduced their stakes in TMO. Proficio Capital Partners LLC boosted its stake in Thermo Fisher Scientific by 71.5% in the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after buying an additional 253 shares during the period. Cribstone Capital Management LLC boosted its stake in Thermo Fisher Scientific by 8.7% in the second quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock valued at $109,000 after buying an additional 50 shares during the period. Shine Investment Advisory Services Inc. bought a new stake in Thermo Fisher Scientific during the second quarter valued at approximately $113,000. Chicago Partners Investment Group LLC bought a new stake in Thermo Fisher Scientific during the second quarter valued at approximately $108,000. Finally, CWM LLC boosted its stake in Thermo Fisher Scientific by 17.0% in the second quarter. CWM LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after buying an additional 103 shares during the period. 83.52% of the stock is currently owned by institutional investors and hedge funds.

TMO has been the subject of several research analyst reports. Bank of America Corporation boosted their price objective on Thermo Fisher Scientific from $190.00 to $200.00 and gave the company a “buy” rating in a report on Tuesday, May 9th. Barclays PLC reissued an “overweight” rating and issued a $190.00 price objective (up from $175.00) on shares of Thermo Fisher Scientific in a report on Tuesday, May 9th. Jefferies Group LLC reissued a “hold” rating and issued a $175.00 price objective on shares of Thermo Fisher Scientific in a report on Wednesday, May 17th. Cantor Fitzgerald initiated coverage on Thermo Fisher Scientific in a report on Thursday, May 18th. They issued an “overweight” rating and a $194.00 price objective for the company. Finally, Deutsche Bank AG set a $200.00 price objective on Thermo Fisher Scientific and gave the company a “buy” rating in a report on Saturday, June 10th. One analyst has rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $188.56.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Insider Buying and Selling by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.